SecBot SecBot
SECBOTREPLAY Home › Report › NBIX

NBIX · Neurocrine Biosciences (NBIX) has entered into a definitive agreement…

NEUROCRINE BIOSCIENCES INC · 8-K filed Apr 6, 2026 at 07:35 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 6, 2026 at 07:35 ET

Neurocrine Biosciences (NBIX) has entered into a definitive agreement to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition will add VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio of first-in-class medicines, strengthening its leadership in endocrinology and rare disease. The deal is expected to close within 90 days, subject to customary closing conditions including regulatory approvals.

  • Neurocrine Biosciences is acquiring Soleno Therapeutics for $53.00 per share in cash.
  • The total transaction equity value is $2.9 billion.
  • The acquisition adds VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio.
  • VYKATTM XR generated $190 million in revenue for Soleno in 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access